Komori
Eisai (4523) · InitiativeFirst stated

E2025による神経変性AD創薬

First written in 2026-08-03. . Latest entry: 2026-08-03.

1entries
1years
1from disclosures
Share on X
How it moved
Same theme, other companies

This thread is not in a theme yet. When the same subject shows up in other companies' filings, you can compare them here.

Full recordFilings, disclosures and news, newest first
  1. 2026-08-03First statedPresentation materials for financial results

    「E2025 （抗EphA4*15抗体） AD Continuum 神経変性 次世代創薬」

    E2025について、ADの神経変性領域におけるフェーズI開発品として初めて記載し、2026年度のCSFバイオマーカーデータ取得予定を示した。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Eisai yet. It last moved in the Presentation materials for financial results of 2026-08-03: "First stated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
E2025による神経変性AD創薬 | Eisai Co.,Ltd. (4523) | Komori